Tumor cell resistance to DNA topoisomerase II inhibitors: New developments

Drug Resistance Updates

Volumn 2, Issue 6, 1999, Pages 382-389

  Beck, William T ^a   Morgan, Susan E ^a   Mo, Yin Yuan ^a   Bhat, Uppoor G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CELL CYCLE PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GYRASE INHIBITOR; PIPERAZINEDIONE; PROTEIN BCL 2; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; CANCER RESISTANCE; CELL MEMBRANE; CELL NUCLEUS; CYTOSOL; DNA METABOLISM; DRUG ACCUMULATION; DRUG TARGETING; GENE MUTATION; GENE OVEREXPRESSION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033502716     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0110     Document Type: Article

References (94)

1. Liu L. F. DNA Topoisomerases. Topoisomerase-targeting drugs. Adv Pharmacol. 29B:1994;1-305.
2. Osheroff N. DNA Topoisomerases. Biochim Biophys Acta. 1400:1998;1-2.
3. Hanai R., Caron P. R., Wang J. C. Human TOP3: a single-copy gene encoding DNA topoisomerase III. Proc Natl Acad Sci USA. 93:1996;3653-3657.
4. Austin C. A., Marsh K. L. Eukaryotic DNA topoisomerase II beta. Bioessays. 20:1998;215-226.
5. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 65:1996;635-692.
6. Osheroff N., Corbett A. H., Robinson M. J. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol. 29B:1994;105-126.
7. Roca J., Ishida R., Berger J. M., Andoh T., Wang J. C. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA. 91:1994;1781-1785.
8. Fortune J. M., Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage. J Biol Chem. 273:1998;17643-17650.
9. Larsen A. K., Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta. 1400:1998;257-274.
10. Choi K. H., Chen C. J., Kriegler M., Roninson I. R. An altered pattern of cross-resistence in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell. 53:1988;519-529.
11. Cole S. P., Bhardwaj G., Gerlach J. H. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654.
12. Kruh G. D., Chan A., Myers K., Gaughan K., Miki T., Aaronson S. A. Expression complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res. 54:1994;1649-1652.
13. Chaudhary P. M., Roninson I. R. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 85:1993;632-639.
14. Koike K., Abe T., Hisano T. Overexpression of multidrug resistance protein gene in human cancer cell lines selected for drug resistance to epipodophyllotoxins. Jpn J Cancer Res. 87:1996;765-772.
15. Wang Q., Beck W. T. Transcriptional suppression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res. 58:1998;5762-5769.
16. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
17. Villunger A., Strasser A. Does "Death Receptor" signaling play a role in tumorigenesis and cancer therapy? Oncology Res. 10:1998;541-550.
18. Kasibhatla S., Brunner T., Genestier L., Echeverri F., Mahboubi A., Green D. R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1:1998;543-551.
19. Mo Y. Y., Beck W. T. DNA damage signals induction of Fas ligand in tumor cells. Mol. Pharmacol. 55:1999;216-222.
20. Magee T., Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell. 98:1999;9-12.
21. Koo H. M., Monks A., Mikheev A. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res. 56:1996;5211-5216.
22. Koo H. M., Gray-Goodrich M., Kohlhagen G. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. J Natl Cancer Inst. 91:1999;236-244.
23. Rubin E., Kharbanda S., Gunji H., Kufe D. Activation of the c-jun protooncogene in human myeloid leukemia cells treated with etoposide. Mol Pharmacol. 39:1991;697-701.
24. Kim R., Beck W. T. Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA binding activity, and formation of Jun/Fos family dimers and their association with intenucleosomal DNA ladders after treatment with VM-26. Cancer Res. 54:1994;4958-4966.
25. Jarvis W. D., Johnson C. R., Fornari F. A., Park J. S., Dent P., Grant S. Evidence that the apoptotic actions of etoposide are independent of c-Jun/activating protein-1-mediated transregulation. J Pharmacol Exptl Ther. 290:1999;1384-1392.
26. Shapiro P. S., Whalen A. M., Tolwinski N. S. Extracellular signal-regulated kinase activates topoisomerase IIα through a mechanism independent of phosphorylation. Mol Cell Biol. 19:1999;3551-3560.
27. Bojanowski K., Maniotis A. J., Plisov S., Larsen A. K., Ingber D. E. DNA topoisomerase II can drive changes in higher order chromosome architecture without enzymatically modifying DNA. J Cell Biochem. 69:1998;127-142.
28. Chauhan D., Hideshima T., Treon S. Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells. Cancer Res. 59:1999;1192-1195.
29. Bhat U. G., Raychaudhuri P., Beck W. T. Functional interaction between human topoisomerase IIα and retinoblastoma protein. Proc Nat Acad Sci USA. 96:1999;7859-7864.
30. Sebolt-Leopold J. S., Dudley D. T., Herrera R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med. 5:1999;810-816.
31. Khélifa T., Beck W. T. Merbarone, a catalytic inhibitor of DNA topoisomerase II, induces apoptosis in CEM cells through activation of ICE/CED-3-like protease. Mol Pharmacol. 55:1999;548-556.
32. Khélifa T., Beck W. T. Induction of apoptosis by ICRF-187 through caspases in absence of c-jun expression and JNK1 activation in VM-26-resistant CEM cells. Biochem Pharmacol. 58:1999;1247-1257.
33. No reference.
34. Willmore E., Frank A. J., Padget K., Tilby M. J., Austin C. A. Etoposide targets topoisomerase II alpha and II beta in leukemic cells: isoform-specific cleavable complexes visualized and quantified in situ by a novel immunofluorescence technique. Mol Pharmacol. 54:1998;78-85.
35. Chen M., Beck W. T. VM-26-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res. 53:1993;5946-5953.
36. Herzog C. E., Holmes K. A., Tuschong L. M., Ganapathi R., Zwelling L. A. Absence of topoisomerase II beta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase II alpha. Cancer Res. 58:1998;5298-5300.
37. Dereuddre S., Delaporte C., Jacquemin-Sablon A. Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors. Cancer Res. 57:1997;4301-4308.
38. Biersack H., Jensen S., Gromova I., Nielsen I. S., Westergaard O., Andersen A. H. Active heterodimers are formed from human DNA topoisomerase II alpha and II beta isoforms. Proc Natl Acad Sci USA. 93:1996;8288-8293.
39. Woessner R. D., Mattern M. R., Mirabelli C. K., Johnson R. K., Drake F. H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2:1991;209-214.
40. Grue P., Grasser A., Sehested M. Essential mitotic functions of DNA topoisomerase II alpha are not adopted by topoisomerase II beta in human H69 cells. J Biol Chem. 273:1998;33660-33666.
41. Nakano H., Yamazaki T., Miyatake S., Nozaki N., Kikuchi A., Saito T. Specific interaction of topoisomerase II beta and the CD3 epsilon chain of the T cell receptor complex. J Biol Chem. 271:1996;6483-6489.
42. Markovits J., Junqua S., Goldwasser F. Genistein resistance in human leukaemic CCRF-CEM cells: selection of diploid cell line with reduced DNA topoisomerase II beta isoform. Biochem Pharmacol. 50:1995;177-186.
43. Isaacs R. J., Davies S. L., Sandri I., Redwood C., Wells N. J., Hickson I. D. Physiological regulation of eukaryotic topoisomerase II. Biochim Biophys Acta. 1400:1998;121-137.
44. Ng S. W., Liu Y., Schnipper L. E. Cloning and characterization of the 5′-flanking sequence for the human DNA topoisomerase II beta gene. Gene. 203:1997;113-119.
45. Beck W. T. DNA topoisomerases and tumor cell resistance to their inhibitors. Shilsky R., Milano G., Ratain M. Principles of cancer drug pharmacology. 1996;Marcel Dekker, Inc. New York.
46. Nitiss J. L., Beck W. T. Anti-topoisomerase drug action and resistance. Eur J Cancer. 32A:1996;958-966.
47. Kaufmann S. H. Resistance to topoisomerase II poisons: is the answer in the promoter? Leukemia Res. 21:1997;1033-1036.
48. Vassetzky Y. S., Alghisi G. C., Gasser S. M. DNA topoisomerase mutations and resistance to anti-tumor drugs. BioEssays. 17:1995;767-774.
49. Hasinoff B. B., Kuschak T. I., Creighton A. M. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II. Biochem Pharmacol. 53:1997;1843-1853.
50. Sehested M., Wessel I., Jensen L. H. Chinese hamster ovar cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: A Tyr49Phe mutation confers high-level resistance to bis-dioxopiperazines. Cancer Res. 58:1998;1460-1468.
51. Wessel I., Jensen L. H., Jensen P. B. Human small cell lung cancer NYH cells selected for resistance to the bis-dioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the α isoform. Cancer Res. 59:1999;3442-3450.
52. Kusumoto H., Rodgers Q. E., Raimondi B. S.C., Beck W. T. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. Cancer Res. 56:1996;2573-2583.
53. Morgan S. E., Cadena R. S., Raimondi S. C., Beck W. T. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerases IIα and altered G2/M checkpoint and apoptotic responses. Mol Pharmacol (in press); 2000.
54. Kubo T., Kohno K., Ohga T. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells. Cancer Res. 55:1995;3860-3864.
55. Hashimoto S., Chatterjee S., Ranjit G. B. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth. Oncol Res. 7:1995;407-416.
56. Son Y. S., Suh J. M., Ahn S. H. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Cancer Chemother Pharmacol. 41:1998;353-360.
57. Matsumoto Y., Takano H., Fojo T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res. 57:1997;5086-5092.
58. Scheltema J. M., Romijn J. C., van Steenbrugge G. J., Beck W. T., Schroder F. H., Mickisch G. H. Decreased levels of topoisomerase II alpha in human renal cell carcinoma lines resistant to etoposide. J Cancer Res Clin Oncol. 123:1997;546-554.
59. Eijdems E. W., de Haas M., Timmerman A. J. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines. Br J Cancer. 71:1995;40-47.
60. Chen M., Beck W. T. Expression, stability and phosphorylation of DNA topoisomerase II isoforms in two VM-26-resistant human leukemic CEM sublines. Oncol Res. 7:1995;103-111.
61. Hochhauser D., Stanway C. A., Harris A. L., Hickson I. D. Cloning and characterization of the 5′-flanking region of the human topoisomerase IIα gene. J Biol Chem. 267:1992;18961-18965.
62. Falck J., Jensen P. B., Sehested M. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIα gene. J Biol Chem. 274:1999;18753-18758.
63. Mo Y., Wang Q., Beck W. T. Down-regulation of topoisomerase IIα in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3. Cancer Res. 57:1997;5004-5008.
64. Morgan, S. E. Beck, W. T. Role of an inverted CCAAT element in human topoisomerase II alpha gene expression in dexrazoxane (ICRF-187)-sensitive and -resistant CEM leukemic cells. J Biol Chem (submitted).
65. Jones P. A. The DNA methylation paradox. Trends Genet. 15:1999;34-37.
66. Nitiss J. L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta. 1400:1998;63-81.
67. Matsumoto Y., Takano H., Fojo T. Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res. 57:1997;5086-5092.
68. Kingma P. S., Burden D. A., Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance. Biochemistry. 38:1999;3457-3461.
69. Kubo A., Yoshikawa A., Hirashima T. Point mutations of the topoisomerase II alpha gene in patients with small cell lung cancer treated with etoposide. Cancer Res. 56:1996;1232-1236.
70. Mirski S. E., Cole S. P. Cytoplasmic localization of mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in drug-resistant human lung cancer cell line. Cancer Res. 55:1995;2129-2134.
71. Mo Y., Beck W. T. Heterogenous expression of DNA topoisomerase IIα isoforms in tumor cell lines. Oncol Res. 9:1997;193-204.
72. Campain J. A., Slovak M. L., Schoenlein P. V., Popescu N. C., Gottesman M. M., Pastan I. Acquisition of multiple copies of a mutant topoisomerase II alpha allele by chromosome 17 aneuploidy is associated with etoposide resistance in human melanoma cell lines. Somat Cell Mol Genet. 21:1995;451-471.
73. Davies S. L., Bergh J., Harris A. L., Hickson I. D. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors. Br J Cancer. 75:1997;816-821.
74. Zhang H., D'Arpa P., Liu L. F. A model for tumor cell killing by topoisomerase poisons. Cancer Cells. 2:1990;23-27.
75. Wang Q., Zambetti G. P., Suttle D. P. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol Cell Biol. 17:1997;389-397.
76. Sandri M. I., Isaacs R. J., Ongkeko W. M. p53 regulates the minimal promoter of the human topoisomerase II alpha gene. Nucleic Acid Res. 24:1996;4434-4470.
77. Land Bax proteins in human leukemic cell lines expressing altered DNA topoisomerase II-associated multidrug resistance (at-MDR). Proc Amer Assn Cancer Res. 37:1996;30.
78. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. p53 mutations in human cancers. Science. 253:1991;49-53.
79. Galimberti S., Marchetti A., Buttitta F. Multidrug resistance related genes and p53 expression in human non-small cell lung cancer. Anticancer Res. 18:1998;2973-2976.
80. Lowe S. W., Ruley H. E., Jacks T., Housman D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
81. Nip J., Strom D. K., Fee B. E., Zambetti G., Cleveland J. L., Hiebert S. W. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-Independent apoptosis. Mol Cell Biol. 17:1997;1049-1056.
82. Kim R., Kusumoto H., Beck W. T. Constitutive overexpression of p53 in VM-26-resistant human leukemia CEM cells. Proc Am Assoc Cancer Res. 36:1995;20.
83. Momand J., Zambetti G. P., Olson D. C., George D., Levine A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 69:1992;1237-1245.
84. Oliner J. D., Pietenpol J. A., Thiagalingam S., Gyuris J., Kinzler K. W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 362:1993;857-860.
85. ARFstabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 96:1999;6937-6941.
86. Morgan, S. E. Kim, R. Wong Pu, Chen, Kusumoto, H. Lu, T. Beck, W. T. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and resistant human leukemic CEM cells (submitted).
87. Holm B., Jensen P. B., Sehested M. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors. Cancer Chemother Pharmacol. 38:1996;203-209.
88. Jensen P. B., Sehested M. DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide. Biochem Pharmacol. 54:1997;755-759.
89. Zhang L., Zhou W., Velculescu V. E. Gene expression profiles in normal and cancer cells. Science. 276:1997;1268-1272.
90. Shim C., Zhang W., Rhee C. H., Lee J. H. Profiling of differentially expressed genes in human primary cervical cancer by complementary DNA expression array. Clin Cancer Res. 4:1998;3045-3050.
91. Schraml P., Kononen J., Bubendorf L. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 5:1999;1966-1975.
92. Bertucci F., Van Hulst S., Bernard K. Expression scanning of an array of growth control genes in human tumor cell lines. Oncogene. 18:1999;3905-3912.
93. Pollack J. R., Perou C. M., Alizadeh A. A. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet. 23:1999;41-46.
94. Hilsenbeck S. G., Friedrichs W. E., Schiff R. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 91:1999;453-459.